Skip to main content
. 2017 Aug 4;292(37):15561–15576. doi: 10.1074/jbc.M117.791343

Figure 1.

Figure 1.

Co-expression of PKM1 and PKM2 in cancer cell lines. A, schematic representation to depict the approach employed to assay PKM1/PKM2 mRNA ratio in human cancer cells as in B. B, semi-quantitative RT-PCR followed by PKM2 exon-specific restriction digestion with Ale I restriction enzyme to examine the proportion of PKM1 and PKM2 expression in human cancer cells. UCT, uncut; Ale I, restriction digested, and D.L., DNA Ladder. Uncut PKM1 and PKM2 397 bp, Ale I undigested PKM1 397 bp, Ale I digested PKM2 product I (249 bp), and Ale I digested PKM2 product II (148 bp). C, immunoblots of PKM1 and PKM2 to demonstrate co-expression of PKM1 and PKM2 isoforms in six human cancer cell lines of four different tissue origins and two noncancerous cell lines, used as a control. D, immunoblotting with anti-PKM1 and anti-PKM2 to show the specificity for purified recombinant PKM1 (rGST-PKM1) and PKM2 (rGST-PKM1), stained with Coomassie Brilliant Blue (C.B.B.).